Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• JonckheereNSkrypekNVan SeuningenIMucins and tumor resistance to chemotherapeutic drugsBiochim Biophys Acta20141846114215124785432
   PubMed Web of Science ®Google Scholar
• ZhaoJCancer stem cells and chemoresistance: the smartest survives the raidPharmacol Ther201616014515826899500
   PubMed Web of Science ®Google Scholar
• DuBShimJSTargeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancerMolecules2016217 pii:E965
   Web of Science ®Google Scholar
• NaguibYWCuiZNanomedicine: the promise and challenges in cancer chemotherapyAdv Exp Med Biol201481120723324683034
   PubMed Web of Science ®Google Scholar
• BoboDRobinsonKJIslamJThurechtKJCorrieSRNanoparticle-based medicines: a review of FDA-approved materials and clinical trials to datePharm Res201633102373238727299311
   PubMed Web of Science ®Google Scholar
• WangAZGuFZhangLBiofunctionalized targeted nanoparticles for therapeutic applicationsExpert Opin Biol Ther2008881063107018613759
   PubMed Web of Science ®Google Scholar
• ZhangLGuFXChanJMWangAZLangerRSFarokhzadOCNanoparticles in medicine: therapeutic applications and developmentsClin Pharmacol Ther200883576176917957183
   PubMed Web of Science ®Google Scholar
• Matray-devotiJCancer DrugsNew YorkChelsea House Publications2006
   Google Scholar
• TeicherBACancer Therapeutics: Experimental and Clinical AgentsTotowa, NJHumana Press1997
   Google Scholar
• LivshitsZRaoRBSmithSWAn approach to chemotherapy-associated toxicityEmerg Med Clin North Am201432116720324275174
   PubMed Web of Science ®Google Scholar
• KibriaGHatakeyamaHHarashimaHCancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery systemArch Pharm Res201437141524272889
   PubMed Web of Science ®Google Scholar
• HolohanCVan SchaeybroeckSLongleyDBJohnstonPGCancer drug resistance: an evolving paradigmNat Rev Cancer2013131071472624060863
   PubMed Web of Science ®Google Scholar
• DrinbergVBitcoverRRajchenbachWPeerDModulating cancer multidrug resistance by sertraline in combination with a nanomedicineCancer Lett2014354229029825173796
   PubMed Web of Science ®Google Scholar
• GengMWangLChenXCaoRLiPThe association between chemosensitivity and Pgp, GST-pi and Topo II expression in gastric cancerDiagn Pathol2013819824326092
   PubMed Web of Science ®Google Scholar
• TurriniEFerruzziLFimognariCNatural compounds to overcome cancer chemoresistance: toxicological and clinical issuesExpert Opin Drug Metab Toxicol201410121677169025339439
   PubMed Web of Science ®Google Scholar
• ProvenzanoPPHingoraniSRHyaluronan, fluid pressure, and stromal resistance in pancreas cancerBr J Cancer201310811823299539
   PubMed Web of Science ®Google Scholar
• PriestmanTCancer Chemotherapy in Clinical PracticeLondonSpringer2008
   Google Scholar
• SarkariaJNKitangeGJJamesCDMechanisms of chemoresistance to alkylating agents in malignant gliomaClin Cancer Res200814102900290818483356
   PubMed Web of Science ®Google Scholar
• FuDCalvoJASamsonLDBalancing repair and tolerance of DNA damage caused by alkylating agentsNat Rev Cancer201212210412022237395
   PubMed Web of Science ®Google Scholar
• BordinDLLimaMLenzGDNA alkylation damage and autophagy inductionMutat Res20137532919923872363
   PubMed Web of Science ®Google Scholar
• SrinivasanAGoldBSmall-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugsFuture Med Chem2012491093111122709253
   PubMed Web of Science ®Google Scholar
• KainaBChristmannMNaumannSRoosWPMGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agentsDNA Repair (Amst)2007681079109917485253
   PubMed Web of Science ®Google Scholar
• TiwariMAntimetabolites: established cancer therapyJ Cancer Res Ther20128451051923361267
   PubMed Web of Science ®Google Scholar
• DeVitaVTJrChuEA history of cancer chemotherapyCancer Res200868218643865318974103
   PubMed Web of Science ®Google Scholar
• TsaiSEvansDBTherapeutic advances in localized pancreatic cancerJAMA Surg2016151986286827276001
   PubMed Web of Science ®Google Scholar
• NagourneyRAFlamMLinkJCarboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancerClin Breast Cancer20088543243518952557
   PubMed Web of Science ®Google Scholar
• PfistererJPlanteMVergoteIGemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJ Clin Oncol200624294699470716966687
   PubMed Web of Science ®Google Scholar
• LongJZhangYYuXOvercoming drug resistance in pancreatic cancerExpert Opin Ther Targets201115781782821391891
   PubMed Web of Science ®Google Scholar
• JordheimLPDumontetCReview of recent studies on resistance to cytotoxic deoxynucleoside analoguesBiochim Biophys Acta20071776213815917881132
   PubMed Web of Science ®Google Scholar
• MarechalRBachetJBMackeyJRLevels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinomaGastroenterology20121433664674e1e622705007
   PubMed Web of Science ®Google Scholar
• CiccoliniJDahanLAndreNCytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapiesJ Clin Oncol201028116016519933910
   PubMed Web of Science ®Google Scholar
• HagnerNJoergerMCancer chemotherapy: targeting folic acid synthesisCancer Manag Res2010229330121301589
   PubMedGoogle Scholar
• PurcellWTEttingerDSNovel antifolate drugsCurr Oncol Rep20035211412512583828
   PubMedGoogle Scholar
• SiddiquiIASannaVImpact of nanotechnology on the delivery of natural products for cancer prevention and therapyMol Nutr Food Res20166061330134126935239
   PubMed Web of Science ®Google Scholar
• OrlikovaBLegrandNPanningJDicatoMDiederichMAnti-inflammatory and anticancer drugs from natureCancer Treat Res201415912314324114478
   PubMedGoogle Scholar
• AirleyRCancer Chemotherapy: Basic Science to the ClinicWest Sussex, UKWiley-Blackwell2009
   Google Scholar
• SmoterMBodnarLDuchnowskaRStecRGralaBSzczylikCThe role of Tau protein in resistance to paclitaxelCancer Chemother Pharmacol201168355355721713447
   PubMed Web of Science ®Google Scholar
• VergaraDTinelliAIannoneAMaffiaMThe impact of proteomics in the understanding of the molecular basis of paclitaxel-resistance in ovarian tumorsCurr Cancer Drug Targets201212898799722515523
   PubMed Web of Science ®Google Scholar
• BarbutiAMChenZSPaclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapyCancers (Basel)2015742360237126633515
   PubMed Web of Science ®Google Scholar
• ShengYYouYChenYDual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancerInt J Pharm2016512111327521706
   PubMedGoogle Scholar
• CoxJWeinmanSMechanisms of doxorubicin resistance in hepatocellular carcinomaHepat Oncol201631575926998221
   PubMed Web of Science ®Google Scholar
• VatsyayanRChaudharyPLelsaniPCRole of RLIP76 in doxorubicin resistance in lung cancerInt J Oncol20093461505151119424567
   PubMed Web of Science ®Google Scholar
• SimkoVTakacovaMDebreovaMDexamethasone downregulates expression of carbonic anhydrase IX via HIF-1alpha and NF-kappaB-dependent mechanismsInt J Oncol20164941277128827431580
   PubMed Web of Science ®Google Scholar
• CookAMMcDonnellAMLakeRANowakAKDexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategiesOncoimmunology201653e106606227141331
   PubMed Web of Science ®Google Scholar
• SchaafMJMCidlowskiJAMolecular mechanisms of glucocorticoid action and resistanceJ Steroid Biochem Mol Biol2002831–5374812650700
   PubMed Web of Science ®Google Scholar
• Rondon-LagosMVillegasVERangelNSanchezMCZaphiropoulosPGTamoxifen resistance: emerging molecular targetsInt J Mol Sci2016178 pii:E1357
   Web of Science ®Google Scholar
• Viedma-RodriguezRBaiza-GutmanLSalamanca-GomezFMechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review)Oncol Rep201432131524841429
   PubMed Web of Science ®Google Scholar
• MacerelliMGanzinelliMGouedardCCan the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?Cancer Treat Rev20164881927262017
   PubMed Web of Science ®Google Scholar
• TapiaGDiaz-PadillaIMolecular mechanisms of platinum resistance in ovarian cancerDiaz-PadillaIOvarian Cancer – A Clinical and Translational UpdateInTechOpen2013205223
   Google Scholar
• RabikCADolanMEMolecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treat Rev200733192317084534
   PubMed Web of Science ®Google Scholar
• ShrivastavaAKhanAAKhurshidMKalamMAJainSKSinghalPKRecent developments in L-asparaginase discovery and its potential as anticancer agentCrit Rev Oncol Hematol201610011025630663
   PubMed Web of Science ®Google Scholar
• AndradeAFBorgesKSSilveiraVSUpdate on the use of l-asparaginase in infants and adolescent patients with acute lymphoblastic leukemiaClin Med Insights Oncol201489510025210485
   PubMedGoogle Scholar
• ChenSHAsparaginase therapy in pediatric acute lymphoblastic leukemia: a focus on the mode of drug resistancePediatr Neonatol201556528729325603726
   PubMed Web of Science ®Google Scholar
• KwaFACole-SinclairMKapuscinskiMChlorambucil-sensitive and -resistant lymphoid cells display different responses to the histone deacetylase inhibitor, sodium butyrateBiochem Biophys Res Commun20104033–428829221075074
   PubMed Web of Science ®Google Scholar
• XiaoSYangZQiuXmiR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectlyOncotarget2016731502295023827384876
   PubMedGoogle Scholar
• PatilRPortilla-AriasJDingHTemozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(beta-L-malic acid)Pharm Res201027112317232920387095
   PubMed Web of Science ®Google Scholar
• OrzaASoritauOTomuleasaCReversing chemoresistance of malignant glioma stem cells using gold nanoparticlesInt J Nanomedicine2013868970223467447
   PubMed Web of Science ®Google Scholar
• DanhierFMessaoudiKLemaireLBenoitJPLagarceFCombined anti-galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluationInt J Pharm20154811–215416125644286
   PubMedGoogle Scholar
• Balca-SilvaJMatiasDdo CarmoATamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell linesBiochim Biophys Acta20151850472273225554223
   PubMed Web of Science ®Google Scholar
• YoshimotoKMizoguchiMHataNComplex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastomaFront Oncol2012218623227453
   PubMedGoogle Scholar
• YangRYYangKSPikeLJMarshallGRTargeting the dimerization of epidermal growth factor receptors with small-molecule inhibitorsChem Biol Drug Des20107611920456371
   PubMed Web of Science ®Google Scholar
• LefrancFSadeghiNCambyIMetensTDewitteOKissRPresent and potential future issues in glioblastoma treatmentExpert Rev Anticancer Ther20066571973216759163
   PubMed Web of Science ®Google Scholar
• MessaoudiKSaulnierPBoesenKBenoitJPLagarceFAnti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomideInt J Nanomedicine201491479149024711698
   PubMed Web of Science ®Google Scholar
• MessaoudiKClavreulADanhierFSaulnierPBenoitJPLagarceFCombined silencing expression of MGMT with EGFR or galectin-1 enhances the sensitivity of glioblastoma to temozolomideEur J Nanomed20157297107
   Google Scholar
• XuHPaxtonJWWuZDevelopment of long-circulating pH-sensitive liposomes to circumvent gemcitabine resistance in pancreatic cancer cellsPharm Res20163371628163726964546
   PubMed Web of Science ®Google Scholar
• ChungWGSandovalMASloatBRLansakaraPDCuiZStearoyl gemcitabine nanoparticles overcome resistance related to the overexpression of ribonucleotide reductase subunit M1J Control Release2012157113214021851843
   PubMed Web of Science ®Google Scholar
• WangJYinCTangGLinXWuQGlucose-functionalized multidrug-conjugating nanoparticles based on amphiphilic terpolymer with enhanced anti-tumorous cell cytotoxicityInt J Pharm20134411–229129823194888
   PubMedGoogle Scholar
• ChengMGaoXWangYSynthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivoMar Drugs20131193517353624048270
   PubMed Web of Science ®Google Scholar
• Johari-AharMBararJAlizadehAMDavaranSOmidiYRashidiMRMethotrexate-conjugated quantum dots: synthesis, characterisation and cytotoxicity in drug resistant cancer cellsJ Drug Target201624212013326176269
   PubMed Web of Science ®Google Scholar
• YuanXJiWChenSA novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multi-drug resistance for lung cancer treatmentInt J Nanomedicine2016112119213127307727
   PubMed Web of Science ®Google Scholar
• WangLJiaEOvarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistanceDrug Deliv20162351810181726530693
   PubMed Web of Science ®Google Scholar
• TangXLiangYFengXZhangRJinXSunLCo-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatmentMater Sci Eng C Mater Biol Appl20154934835525686959
   PubMed Web of Science ®Google Scholar
• SongXRZhengYHeGDevelopment of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinomaJ Pharm Sci201099124874487920821385
   PubMed Web of Science ®Google Scholar
• TacarOSriamornsakPDassCRDoxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systemsJ Pharm Pharmacol201365215717023278683
   PubMed Web of Science ®Google Scholar
• KopeckaJPortoSLusaSZoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumorsOncotarget2016715207532077226980746
   PubMed Web of Science ®Google Scholar
• YangHDengLLiTMultifunctional PLGA nanobubbles as theranostic agents: combining doxorubicin and P-gp siRNA co-delivery into human breast cancer cells and ultrasound cellular imagingJ Biomed Nanotechnol201511122124213626510307
   PubMed Web of Science ®Google Scholar
• WangXTengZWangHIncreasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery systemInt J Clin Exp Pathol2014741337134724817930
   PubMed Web of Science ®Google Scholar
• YuCZhouMZhangXWeiWChenXZhangXSmart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosisNanoscale20157135683569025740312
   PubMed Web of Science ®Google Scholar
• UnsoyGKhodadustRYalcinSMutluPGunduzUSynthesis of doxorubicin loaded magnetic chitosan nanoparticles for pH responsive targeted drug deliveryEur J Pharm Sci20146224325024931189
   PubMed Web of Science ®Google Scholar
• GeneraliDBerrutiACappellettiMREffect of primary letrozole treatment on tumor expression of mTOR and HIF-1alpha and relation to clinical responseJ Natl Cancer Inst Monogr2015201551646626063890
   PubMedGoogle Scholar
• HoeflichKPGuanJEdgarKAThe PI3K inhibitor taselisib overcomes letrozole resistance in a breast cancer model expressing aromataseGenes Cancer201673–4738527382432
   PubMedGoogle Scholar
• NairHBHuffmanSVeerapaneniPHyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in miceJ Nanosci Nanotechnol20111153789379921780370
   PubMed Web of Science ®Google Scholar
• ChoSKPedramALevinERKwonYJAcid-degradable core-shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD)Biomaterials20133438102281023724055523
   PubMed Web of Science ®Google Scholar
• DilrubaSKalaydaGVPlatinum-based drugs: past, present and futureCancer Chemother Pharmacol20167761103112426886018
   PubMed Web of Science ®Google Scholar
• ZhouDCongYQiYOvercoming tumor resistance to cisplatin through micelle-mediated combination chemotherapyBiomater Sci20153118219126214201
   PubMed Web of Science ®Google Scholar
• ScaranoWde SouzaPStenzelMHDual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancerBiomater Sci20153116317426214199
   PubMed Web of Science ®Google Scholar
• JainRKStylianopoulosTDelivering nanomedicine to solid tumorsNat Rev Clin Oncol201071165366420838415
   PubMed Web of Science ®Google Scholar
• OwensDE3rdPeppasNAOpsonization, biodistribution, and pharmacokinetics of polymeric nanoparticlesInt J Pharm200630719310216303268
   PubMed Web of Science ®Google Scholar
• GaoHHeQThe interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behaviorExpert Opin Drug Deliv201411340942024397260
   PubMed Web of Science ®Google Scholar
• RattanRBhattacharjeeSZongHNanoparticle-macrophage interactions: a balance between clearance and cell-specific targetingBioorg Med Chem201725164487449628705434
   PubMed Web of Science ®Google Scholar
• ChrastinaAMasseyKASchnitzerJEOvercoming in vivo barriers to targeted nanodeliveryWiley Interdiscip Rev Nanomed Nanobiotechnol20113442143721538941
   PubMed Web of Science ®Google Scholar
• StylianopoulosTIntelligent drug delivery systems for the treatment of solid tumorsEur J Nanomed201681916
   Google Scholar
• EwaldBSampathDPlunkettWNucleoside analogs: molecular mechanisms signaling cell deathOncogene200827506522653718955977
   PubMed Web of Science ®Google Scholar
• WongASooRAYongWPInnocentiFClinical pharmacology and pharmacogenetics of gemcitabineDrug Metab Rev2009412778819514966
   PubMed Web of Science ®Google Scholar
• KimTMKimSAhnYOLeeSHKimDWHeoDSAnti-cancer activity of gemcitabine against natural killer cell leukemia/lymphomaLeuk Lymphoma201455494094323772641
   PubMed Web of Science ®Google Scholar
• EdwardCPhysicians’ Cancer Chemotherapy Drug Manual 2015Burlington, MAJones and Bartlett Publishers2015
   Google Scholar
• FanPLiuLYinYMicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancerCancer Lett2016373113013726828016
   PubMed Web of Science ®Google Scholar
• OrlandiACalegariMAMartiniMGemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worseClin Transl Oncol2016181098899526742940
   PubMed Web of Science ®Google Scholar
• OhmineKKawaguchiKOhtsukiSAttenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cellsPharm Res20122972006201622419259
   PubMed Web of Science ®Google Scholar
• SongYBabaTMukaidaNGemcitabine induces cell senescence in human pancreatic cancer cell linesBiochem Biophys Res Commun2016477351551927311854
   PubMed Web of Science ®Google Scholar
• HuangPChubbSHertelLWGrindeyGBPlunkettWAction of 2′,2′-difluorodeoxycytidine on DNA synthesisCancer Res19915122611061171718594
   PubMed Web of Science ®Google Scholar
• ElnaggarMGiovannettiEPetersGJMolecular targets of gemcitabine action: rationale for development of novel drugs and drug combinationsCurr Pharm Des201218192811282922390765
   PubMed Web of Science ®Google Scholar
• ShaoJLiuXZhuLYenYTargeting ribonucleotide reductase for cancer therapyExpert Opin Ther Targets201317121423143724083455
   PubMed Web of Science ®Google Scholar
• GestoDSCerqueiraNMFernandesPARamosMJGemcitabine: a critical nucleoside for cancer therapyCurr Med Chem20121971076108722257063
   PubMed Web of Science ®Google Scholar
• CiccoliniJSerdjebiCPetersGJGiovannettiEPharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveCancer Chemother Pharmacol201678111227007129
   PubMed Web of Science ®Google Scholar
• MoriRIshikawaTIchikawaYHuman equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cellsOncol Rep20071751201120517390066
   PubMed Web of Science ®Google Scholar
• FarrellJJElsalehHGarciaMHuman equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancerGastroenterology2009136118719518992248
   PubMed Web of Science ®Google Scholar
• WangCZhangWFuMYangAHuangHXieJEstablishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpressionOncol Rep201433138339025394408
   PubMed Web of Science ®Google Scholar
• WeizmanNKrelinYShabtay-OrbachAMacrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminaseOncogene201433293812381923995783
   PubMed Web of Science ®Google Scholar
• HuangYLiuXWangYHThe prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancersUrol Oncol201432151.e919
   PubMed Web of Science ®Google Scholar
• GalmariniCMClarkeMLFaletteNPuisieuxAMackeyJRDumontetCExpression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabineInt J Cancer200297443944511802204
   PubMed Web of Science ®Google Scholar
• SkrypekNDucheneBHebbarMLeteurtreEvan SeuningenIJonckheereNThe MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter familyOncogene201332131714172322580602
   PubMed Web of Science ®Google Scholar
• RudinDLiLNiuNGemcitabine cytotoxicity: interaction of efflux and deaminationJ Drug Metab Toxicol2011210711021804948
   PubMedGoogle Scholar
• WattanawongdonWHahnvajanawongCNamwatNEstablishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasivenessInt J Oncol201547139841025998688
   PubMed Web of Science ®Google Scholar
• MackeyJRYaoSYSmithKMGemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transportersJ Natl Cancer Inst199991211876188110547395
   PubMedGoogle Scholar
• MackeyJRManiRSSelnerMFunctional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell linesCancer Res19985819434943579766663
   PubMed Web of Science ®Google Scholar
• SpratlinJSanghaRGlubrechtDThe absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinomaClin Cancer Res200410206956696115501974
   PubMed Web of Science ®Google Scholar
• BrandiGDesertiMVasuriFMembrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patientsOncologist201621560060727032872
   PubMed Web of Science ®Google Scholar
• LiuZQHanYCZhangXPrognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysisPLoS One201491e8710324475233
   PubMed Web of Science ®Google Scholar
• EspinozaJAGarciaPBizamaCLow expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naive pT2 gallbladder adenocarcinoma patientsHistopathology201668572272826266900
   PubMed Web of Science ®Google Scholar
• GiovannettiEDel TaccaMMeyVTranscription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabineCancer Res20066673928393516585222
   PubMed Web of Science ®Google Scholar
• BirdNTElmasryMJonesRImmunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapyBr J Surg2017104432833628199010
   PubMed Web of Science ®Google Scholar
• NakanoTSaikiYKudoCAcquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCKBiochem Biophys Res Commun201546441084108926196746
   PubMed Web of Science ®Google Scholar
• ShimadaYOkumuraTSekineSClinicopathological significance of deoxycytidine kinase expression in esophageal squamous cell carcinomaMol Clin Oncol20131471672024649234
   PubMedGoogle Scholar
• JordheimLPCrosEGouyMHCharacterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrugClin Cancer Res200410165614562115328204
   PubMed Web of Science ®Google Scholar
• GalmariniCMClarkeMLJordheimLResistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase geneBMC Pharmacol20044815157282
   PubMedGoogle Scholar
• JordheimLPGalmariniCMDumontetCGemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cellsCancer Chemother Pharmacol200658454755416463058
   PubMed Web of Science ®Google Scholar
• KazunoHSakamotoKFujiokaAFukushimaMMatsudaASasakiTPossible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell lineCancer Sci200596529530215904471
   PubMed Web of Science ®Google Scholar
• KroepJRLovesWJvan der WiltCLPretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivityMol Cancer Ther20021637137612477049
   PubMed Web of Science ®Google Scholar
• SebastianiVRicciFRubio-ViqueiraBImmunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survivalClin Cancer Res20061282492249716638857
   PubMed Web of Science ®Google Scholar
• FujitaHOhuchidaKMizumotoKGene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapyNeoplasia2010121080780820927319
   PubMed Web of Science ®Google Scholar
• BouffardDYLaliberteJMomparlerRLKinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminaseBiochem Pharmacol1993459185718618494545
   PubMed Web of Science ®Google Scholar
• YoonKAWooSMHongEKCytidine deaminase as a molecular predictor of gemcitabine response in patients with biliary tract cancerOncology201589634535026418006
   PubMed Web of Science ®Google Scholar
• OkazakiTJavleMTanakaMAbbruzzeseJLLiDSingle nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicityClin Cancer Res201016132032920028759
   PubMed Web of Science ®Google Scholar
• TibaldiCGiovannettiEVasileECorrelation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patientsClin Cancer Res20081461797180318347182
   PubMed Web of Science ®Google Scholar
• GilbertJASalavaggioneOEJiYGemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomicsClin Cancer Res20061261794180316551864
   PubMed Web of Science ®Google Scholar
• JordheimLPSèvePTrédanODumontetCThe ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancerLancet Oncol201112769370221163702
   PubMed Web of Science ®Google Scholar
• IwamotoKNakashiroKTanakaHTokuzenNHamakawaHRibonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinomaInt J Oncol20154651971197725738429
   PubMed Web of Science ®Google Scholar
• WangXZhenchukAWimanKGAlbertioniFRegulation of p53R2 and its role as potential target for cancer therapyCancer Lett200927611718760875
   PubMed Web of Science ®Google Scholar
• NordlundNReichardPRibonucleotide reductasesAnnu Rev Biochem20067568170616756507
   PubMed Web of Science ®Google Scholar
• ZengCFanWZhangXRRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients – a short reportCell Oncol (Dordr)201538431932526092210
   PubMed Web of Science ®Google Scholar
• NakanoKBálintEAshcroftMVousdenKHA ribonucleotide reductase gene is a transcriptional target of p53 and p73Oncogene200019374283428910980602
   PubMed Web of Science ®Google Scholar
• ChoECKuoMLLiuXYTumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patientsOncotarget20145134834484424947616
   PubMedGoogle Scholar
• LeccaPMethods of biological network inference for reverse engineering cancer chemoresistance mechanismsDrug Discov Today201419215116324211413
   PubMed Web of Science ®Google Scholar
• NakahiraSNakamoriSTsujieMInvolvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancerInt J Cancer200712061355136317131328
   PubMed Web of Science ®Google Scholar
• ItoiTSofuniAFukushimaNRibonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomasJ Gastroenterol200742538939417530364
   PubMed Web of Science ®Google Scholar
• AkitaHZhengZTakedaYSignificance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinomaOncogene200928322903290919543324
   PubMed Web of Science ®Google Scholar
• CeppiPVolanteMNovelloSERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineAnn Oncol200617121818182516980606
   PubMed Web of Science ®Google Scholar
• KozinnSIHartyNJDelongJMMicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell LinesGenes Cancer201341–2616923946872
   PubMedGoogle Scholar
• NeesseAMichlPFreseKKStromal biology and therapy in pancreatic cancerGut201160686186820966025
   PubMed Web of Science ®Google Scholar
• XuMLiLLiuZABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistanceCancer Lett2013333215215823340176
   PubMed Web of Science ®Google Scholar
• KuramitsuYTabaKRyozawaSIdentification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometryAnticancer Res20103093367337220944110
   PubMed Web of Science ®Google Scholar
• FeigCGopinathanANeesseAChanDSCookNTuvesonDAThe pancreas cancer microenvironmentClin Cancer Res201218164266427622896693
   PubMed Web of Science ®Google Scholar
• MittalAChitkaraDBehrmanSWMahatoRIEfficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancerBiomaterials201435257077708724836307
   PubMed Web of Science ®Google Scholar
• MengHZhaoYDongJTwo-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in miceACS Nano2013711100481006524143858
   PubMed Web of Science ®Google Scholar
• LicciardiMPaolinoDCeliaCGiammonaGCavallaroGFrestaMFolate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugsBiomaterials201031287340735420609469
   PubMed Web of Science ®Google Scholar
• VenturaCACannavaCStancanelliRGemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluationBiomed Microdevices201113579980721607718
   PubMed Web of Science ®Google Scholar
• JiaLPreparation, physicochemical characterization and cytotoxicityin vitroof gemcitabine-loaded PEG-PDLLA nanovesiclesWorld J Gastroenterol2010168100820180242
   PubMed Web of Science ®Google Scholar
• ZhaoLPXueCZhangJWExpression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinomaChin J Cancer2012311047648322692073
   PubMedGoogle Scholar
• XieHJiangWJiangJPredictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinomaCancer2013119117318122736490
   PubMed Web of Science ®Google Scholar
• LeeJJMaengCHBaekSKThe immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)Lung Cancer201070220521020223551
   PubMed Web of Science ®Google Scholar
• UlkerMDumanBBSahinBGumurduluDERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabineContemp Oncol (Pozn)201519320721326557761
   PubMedGoogle Scholar
• GongWZhangXWuJRRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysisLung Cancer201275337438021889227
   PubMed Web of Science ®Google Scholar
• KhatriNRathiMBaradiaDMisraAcRGD grafted siRNA nano-constructs for chemosensitization of gemcitabine hydrochloride in lung cancer treatmentPharm Res201532380681824792823
   PubMed Web of Science ®Google Scholar
• WongananPChungWGZhuSKiguchiKDigiovanniJCuiZSilencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cellsCancer Biol Ther2012131090891422785206
   PubMed Web of Science ®Google Scholar
• DamarajuVLDamarajuSYoungJDNucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapyOncogene200322477524753614576856
   PubMed Web of Science ®Google Scholar
• MarechalRMackeyJRLaiRHuman equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinomaClin Cancer Res20091582913291919318496
   PubMed Web of Science ®Google Scholar
• GreenhalfWGhanehPNeoptolemosJPPancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialJ Natl Cancer Inst20141061djt34724301456
   PubMedGoogle Scholar
• NakagawaNMurakamiYUemuraKCombined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resectionSurgery2013153456557523253379
   PubMed Web of Science ®Google Scholar
• MorinagaSNakamuraYWatanabeTImmunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapyAnn Surg Oncol201219Suppl 3S558S56421913012
   PubMed Web of Science ®Google Scholar
• KondoNMurakamiYUemuraKCombined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resectionAnn Surg Oncol201219Suppl 3S646S65522086444
   PubMedGoogle Scholar
• WongananPLansakaraPDZhuSJust getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle’s ability to overcome gemcitabine resistance caused by RRM1 overexpressionJ Control Release20131691–2172723570983
   PubMed Web of Science ®Google Scholar
• HungSWMarracheSCumminsSDefective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approachCancer Lett2015359223324025600708
   PubMed Web of Science ®Google Scholar
• FreseKKNeesseACookNnab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancerCancer Discov20122326026922585996
   PubMed Web of Science ®Google Scholar
• CouvreurPStellaBReddyLHSqualenoyl nanomedicines as potential therapeuticsNano Lett20066112544254817090088
   PubMed Web of Science ®Google Scholar
• RejibaSReddyLHBigandCParmentierCCouvreurPHajriASqualenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancerNanomedicine20117684184921419876
   PubMed Web of Science ®Google Scholar
• ReddyLHFerreiraHDubernetCSqualenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanismsAnticancer Drugs20081910999100618827565
   PubMed Web of Science ®Google Scholar
• ReddyLHDubernetCMouelhiSLMarquePEDesmaeleDCouvreurPA new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia typesJ Control Release20071241–2202717878060
   PubMed Web of Science ®Google Scholar
• SloatBRSandovalMALiDIn vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticlesInt J Pharm20114091–227828821371545
   PubMedGoogle Scholar
• LansakaraPDRodriguezBLCuiZSynthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticlesInt J Pharm20124291–212313422425885
   PubMedGoogle Scholar
• MengHWangMLiuHUse of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in miceACS Nano2015943540355725776964
   PubMed Web of Science ®Google Scholar
• IyerAKKhaledGFangJMaedaHExploiting the enhanced permeability and retention effect for tumor targetingDrug Discov Today20061117–1881281816935749
   PubMed Web of Science ®Google Scholar
• MatsumuraYMaedaHA new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancsCancer Res19864612 Pt 1638763922946403
   PubMed Web of Science ®Google Scholar
• AcharyaSSahooSKPLGA nanoparticles containing various anti-cancer agents and tumour delivery by EPR effectAdv Drug Deliv Rev201163317018320965219
   PubMed Web of Science ®Google Scholar
• MaedaHNakamuraHFangJThe EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivoAdv Drug Deliv Rev2013651717923088862
   PubMed Web of Science ®Google Scholar
• FangJNakamuraHMaedaHThe EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdv Drug Deliv Rev201163313615120441782
   PubMed Web of Science ®Google Scholar
• XuYMengHDuFPreparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing miceInt J Pharm2015495279279726410754
   PubMed Web of Science ®Google Scholar
• SobotDMuraSRouquetteMCirculating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer CellsMol Ther20172571596160528606375
   PubMed Web of Science ®Google Scholar
• MoysanEBastiatGBenoitJPGemcitabine versus modified gemcitabine: a review of several promising chemical modificationsMol Pharm201310243044422978251
   PubMed Web of Science ®Google Scholar
• FedericoCMorittuVMBrittiDTrapassoECoscoDGemcitabine-loaded liposomes: rationale, potentialities and future perspectivesInt J Nanomedicine201275423543623139626
   PubMed Web of Science ®Google Scholar
• ZhuSWongananPLansakaraPDO’MaryHLLiYCuiZThe effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpressionBiomaterials20133492327233923261218
   PubMed Web of Science ®Google Scholar
• PapaALBasuSSenguptaPBanerjeeDSenguptaSHarfoucheRMechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cellsBMC cancer20121241922998550
   PubMed Web of Science ®Google Scholar
• DamanZOstadSAminiMGilaniKPreparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticlesInt J Pharm20144681–214215124731731
   PubMedGoogle Scholar
• PapaALSidiquiABalasubramanianSUPEGylated liposomal gemcitabine: insights into a potential breast cancer therapeuticCell Oncol (Dordr)201336644945724081907
   PubMed Web of Science ®Google Scholar
• NyhanWNucleotide Synthesis Via Salvage PathwayeLSChichesterJohn Wiley & Sons Ltd2005
   Google Scholar
• KangNJunAHBhutiaYDKannanNUnadkatJDGovindarajanRHuman equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stabilityJ Biol Chem201028536283432835220595384
   PubMed Web of Science ®Google Scholar
• JiangJNeubauerBLGraffJRExpression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinomaAm J Pathol2002160266767111839587
   PubMed Web of Science ®Google Scholar
• AbeTSakamotoKKamoharaHHiranoYKuwaharaNOgawaMGroup II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancerInt J Cancer19977432452509221799
   PubMed Web of Science ®Google Scholar
• OkaYOgawaMMatsudaYSerum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumorsEnzyme199043280881702053
   PubMedGoogle Scholar
• QuachNDMockJNScholpaNERole of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cellsMol Pharm201411103443345125189995
   PubMedGoogle Scholar
• MockJNCostynLJWildingSLArnoldRDCummingsBSEvidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancerIntegr Biol (Camb)20135117218222890797
   PubMed Web of Science ®Google Scholar
• ZhuGMockJNAljuffaliICummingsBSArnoldRDSecretory phospholipase A(2) responsive liposomesJ Pharm Sci201110083146315921455978
   PubMed Web of Science ®Google Scholar
• HofmannDMesserschmidtCBannwarthMBLandfesterKMailanderVDrug delivery without nanoparticle uptake: delivery by a kiss-and-run mechanism on the cell membraneChem Commun (Camb)201450111369137124346146
   PubMed Web of Science ®Google Scholar
• MarkmanJLRekechenetskiyAHollerELjubimovaJYNanomedicine therapeutic approaches to overcome cancer drug resistanceAdv Drug Deliv Rev20136513–141866187924120656
   PubMed Web of Science ®Google Scholar
• CoscoDRoccoFCerutiMVonoMFrestaMPaolinoDSelf-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseasesInt J Nanomedicine201272535254622679366
   PubMed Web of Science ®Google Scholar
• AryaGVandanaMAcharyaSSahooSKEnhanced antiproliferative activity of herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapyNanomedicine20117685987021550422
   PubMed Web of Science ®Google Scholar
• LiJDiYJinCGemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivoNanoscale Res Lett20138117623594566
   PubMed Web of Science ®Google Scholar
• MaksimenkoACaronJMouginJDesmaeleDCouvreurPGemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassembliesInt J Pharm20154821–2384625448549
   PubMedGoogle Scholar
• XuHTPaxtonJWWuZMDevelopment of long-circulating pH-sensitive liposomes to circumvent gemcitabine resistance in pancreatic cancer cellsPharm Res-Dordr201633716281637
   PubMed Web of Science ®Google Scholar
• ChitkaraDMittalABehrmanSWKumarNMahatoRISelf-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinomaBioconjug Chem20132471161117323758084
   PubMed Web of Science ®Google Scholar